{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:28:02Z","timestamp":1790836082301,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T00:00:00Z","timestamp":1573171200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005075","name":"Graduate School of Medical Sciences, University of Groningen, University Medical Center Groningen, the Netherlands","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005075","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ctrv.2019.101931","type":"journal-article","created":{"date-parts":[[2019,11,11]],"date-time":"2019-11-11T11:30:16Z","timestamp":1573471816000},"page":"101931","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"special_numbering":"C","title":["Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma"],"prefix":"10.1016","volume":"82","author":[{"given":"Johanna","family":"Veldman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Visser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke van den","family":"Berg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjan","family":"Diepstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2019.101931_b0005","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-18-1538","article-title":"Immunotherapy in non-small cell lung cancer: facts and hopes","author":"Doroshow","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101931_b0010","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1182\/bloodadvances.2017012534","article-title":"Checkpoint blockade in Hodgkin and non-Hodgkin lymphoma","volume":"1","author":"Merryman","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2019.101931_b0015","article-title":"Role of anti-PD-1 antibodies in advanced melanoma: the era of immunotherapy","volume":"10","author":"Sahni","year":"2018","journal-title":"Cureus"},{"key":"10.1016\/j.ctrv.2019.101931_b0020","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1158\/2159-8290.CD-18-0367","article-title":"Fundamental mechanisms of immune checkpoint blockade therapy","volume":"8","author":"Wei","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2019.101931_b0025","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2019.101931_b0030","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7\u20131 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.ctrv.2019.101931_b0035","doi-asserted-by":"crossref","first-page":"4993","DOI":"10.1073\/pnas.1705327114","article-title":"Proliferation of PD-1+ CD8 T cells in peripheral blood after PD-1-targeted therapy in lung cancer patients","volume":"114","author":"Kamphorst","year":"2017","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2019.101931_b0040","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/nature13954","article-title":"PD-1 blockade induces responses by inhibiting adaptive immune resistance","volume":"515","author":"Tumeh","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2019.101931_b0045","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2017.434","article-title":"Mechanisms of resistance to immune checkpoint inhibitors","volume":"118","author":"Jenkins","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2019.101931_b0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2019.101931_b0055","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0060","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1126\/science.aaa1348","article-title":"Cancer immunology. mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer","volume":"348","author":"Rizvi","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2019.101931_b0065","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0070","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/2159-8290.CD-16-0828","article-title":"Evolution of neoantigen landscape during immune checkpoint blockade in non-small cell lung cancer","volume":"7","author":"Anagnostou","year":"2017","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2019.101931_b0075","doi-asserted-by":"crossref","first-page":"eaar3342","DOI":"10.1126\/scitranslmed.aar3342","article-title":"MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma","volume":"10","author":"Rodig","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0080","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nrc3245","article-title":"The immune contexture in human tumours: impact on clinical outcome","volume":"12","author":"Fridman","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2019.101931_b0085","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2019.101931_b0090","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20130066","article-title":"Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4","volume":"210","author":"Holmgaard","year":"2013","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0095","doi-asserted-by":"crossref","first-page":"120360","DOI":"10.1172\/jci.insight.120360","article-title":"Tumor-specific MHC-II expression drives a unique pattern of resistance to immunotherapy via LAG-3\/FCRL6 engagement","volume":"3","author":"Johnson","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ctrv.2019.101931_b0100","doi-asserted-by":"crossref","first-page":"10501","DOI":"10.1038\/ncomms10501","article-title":"Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints","volume":"7","author":"Koyama","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ctrv.2019.101931_b0105","doi-asserted-by":"crossref","first-page":"237ra67","DOI":"10.1126\/scitranslmed.3007974","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6","author":"Highfill","year":"2014","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0110","doi-asserted-by":"crossref","first-page":"eaal3604","DOI":"10.1126\/scitranslmed.aal3604","article-title":"In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy","volume":"9","author":"Arlauckas","year":"2017","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0115","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","article-title":"Adenosine receptor 2A blockade increases the efficacy of Anti-PD-1 through enhanced antitumor T-cell responses","volume":"3","author":"Beavis","year":"2015","journal-title":"Cancer Immunol Res"},{"issue":"219","key":"10.1016\/j.ctrv.2019.101931_b0120","article-title":"Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?","volume":"16","author":"Botticelli","year":"2018","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0125","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1158\/2159-8290.CD-17-1033","article-title":"CD38-Mediated Immunosuppression as a Mechanism of Tumor Cell Escape from PD-1\/PD-L1 Blockade","volume":"8","author":"Chen","year":"2018","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2019.101931_b0130","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1158\/2159-8290.CD-16-1223","article-title":"Primary resistance to PD-1 blockade mediated by JAK1\/2 mutations","volume":"7","author":"Shin","year":"2017","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ctrv.2019.101931_b0135","article-title":"Adaptive resistance to anti-PD1 therapy by Tim-3 upregulation is mediated by the PI3K-Akt pathway in head and neck cancer","volume":"6","author":"Shayan","year":"2016","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2019.101931_b0140","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1158\/2326-6066.CIR-15-0210","article-title":"PD-1 blockade expands intratumoral memory T Cells","volume":"4","author":"Ribas","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2019.101931_b0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2019.101931_b0150","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2019.101931_b0155","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2019.101931_b0160","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1126\/science.aao4572","article-title":"Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy","volume":"359","author":"Chowell","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2019.101931_b0165","unstructured":"Stein H, Pileri S, Weiss L. Classical Hodgkin lymphoma, Introduction. In: Swerdlow SH, Campo E, Harris NL, et al, eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.Revised Fourth Edition. Lyon, France: IARC; 2017: 424-430."},{"key":"10.1016\/j.ctrv.2019.101931_b0170","doi-asserted-by":"crossref","first-page":"10962","DOI":"10.1073\/pnas.91.23.10962","article-title":"Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development","volume":"91","author":"Kuppers","year":"1994","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ctrv.2019.101931_b0175","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/j.1365-2559.1987.tb01869.x","article-title":"Expression of lymphoid-associated antigens on Hodgkin's and Reed-Sternberg cells of Hodgkin's disease. An immunocytochemical study on lymph node cytospins using monoclonal antibodies","volume":"11","author":"Falini","year":"1987","journal-title":"Histopathology"},{"key":"10.1016\/j.ctrv.2019.101931_b0180","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1182\/blood.V95.4.1443.004k55_1443_1450","article-title":"Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription","volume":"95","author":"Marafioti","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0185","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1182\/blood-2002-03-0839","article-title":"Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma","volume":"101","author":"Schwering","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0190","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0950-3536(96)80020-5","article-title":"Immunology of Hodgkin's disease","volume":"9","author":"Poppema","year":"1996","journal-title":"Baillieres Clin Haematol"},{"key":"10.1016\/j.ctrv.2019.101931_b0195","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1038\/labinvest.2008.24","article-title":"The CD4+CD26- T-cell population in classical Hodgkin's lymphoma displays a distinctive regulatory T-cell profile","volume":"88","author":"Ma","year":"2008","journal-title":"Lab Invest"},{"key":"10.1016\/j.ctrv.2019.101931_b0200","first-page":"351","article-title":"The nature of the lymphocytes surrounding Reed-Sternberg cells in nodular lymphocyte predominance and in other types of Hodgkin's disease","volume":"135","author":"Poppema","year":"1989","journal-title":"Am J Pathol"},{"key":"10.1016\/j.ctrv.2019.101931_b0205","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3109\/10428199609051610","article-title":"CD45 (leucocyte common antigen) expression in T and B lymphocyte subsets","volume":"20","author":"Poppema","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.ctrv.2019.101931_b0210","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1136\/jcp.2007.050146","article-title":"Contribution of the Epstein Barr virus to the molecular pathogenesis of Hodgkin lymphoma","volume":"60","author":"Kapatai","year":"2007","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.ctrv.2019.101931_b0215","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1182\/blood-2011-03-343921","article-title":"A genome-wide meta-analysis of nodular sclerosing Hodgkin lymphoma identifies risk loci at 6p21.32","volume":"119","author":"Cozen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0220","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1093\/jnci\/djr516","article-title":"Genome-wide association study of classical Hodgkin lymphoma and Epstein-Barr virus status-defined subgroups","volume":"104","author":"Urayama","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2019.101931_b0225","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1182\/blood-2007-05-086934","article-title":"HLA-A*02 is associated with a reduced risk and HLA-A*01 with an increased risk of developing EBV+ Hodgkin lymphoma","volume":"110","author":"Niens","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0230","article-title":"HLA associations in classical Hodgkin lymphoma: EBV status matters","volume":"7","author":"Huang","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.101931_b0235","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/S0140-6736(05)66780-3","article-title":"Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus-negative Hodgkin's lymphoma","volume":"365","author":"Diepstra","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2019.101931_b0240","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1158\/1055-9965.EPI-14-0683","article-title":"Genetic associations in classical hodgkin lymphoma: a systematic review and insights into susceptibility mechanisms","volume":"23","author":"Kushekhar","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"10.1016\/j.ctrv.2019.101931_b0245","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1295202","article-title":"HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?","volume":"6","author":"Nijland","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2019.101931_b0250","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/cei.12716","article-title":"The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma","volume":"183","author":"Jones","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.ctrv.2019.101931_b0255","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0260","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1158\/1078-0432.CCR-11-1942","article-title":"Constitutive AP-1 activity and EBV infection induce PD-L1 in Hodgkin lymphomas and posttransplant lymphoproliferative disorders: implications for targeted therapy","volume":"18","author":"Green","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101931_b0265","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1182\/blood.V92.3.1020","article-title":"Antigen presenting phenotype of Hodgkin Reed-Sternberg cells: analysis of the HLA class I processing pathway and the effects of interleukin-10 on epstein-barr virus-specific cytotoxic T-cell recognition","volume":"92","author":"Lee","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0270","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1182\/blood.V92.7.2477","article-title":"Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease","volume":"92","author":"Murray","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0275","doi-asserted-by":"crossref","first-page":"3844","DOI":"10.1182\/blood.V87.9.3844.bloodjournal8793844","article-title":"Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease","volume":"87","author":"Oudejans","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0280","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood-2017-03-770719","article-title":"Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma","volume":"130","author":"Carey","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0285","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1200\/JCO.2017.77.3994","article-title":"Major histocompatibility complex class ii and programmed death ligand 1 expression predict outcome after programmed death 1 blockade in classic hodgkin lymphoma","volume":"36","author":"Roemer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2019.101931_b0290","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1007\/s00432-019-02879-2","article-title":"The role of PD-1\/PD-L1 axis and macrophage in the progression and treatment of cancer","volume":"145","author":"Cai","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.101931_b0295","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2019.101931_b0300","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1172\/JCI99317","article-title":"Contribution of NK cells to immunotherapy mediated by PD-1\/PD-L1 blockade","volume":"128","author":"Hsu","year":"2018","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ctrv.2019.101931_b0305","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","article-title":"Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL","volume":"131","author":"Vari","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0310","doi-asserted-by":"crossref","first-page":"6143","DOI":"10.1038\/onc.2017.209","article-title":"Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers","volume":"36","author":"Liu","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.ctrv.2019.101931_b0315","doi-asserted-by":"crossref","first-page":"5368","DOI":"10.1158\/1078-0432.CCR-18-1038","article-title":"Resistance to radiotherapy and PD-L1 blockade is mediated by TIM-3 upregulation and regulatory T-cell infiltration","volume":"24","author":"Oweida","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101931_b0320","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.26","article-title":"The microenvironment of classical Hodgkin lymphoma: heterogeneity by Epstein-Barr virus presence and location within the tumor","volume":"6","author":"Wu","year":"2016","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctrv.2019.101931_b0325","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2141.2007.06964.x","article-title":"Serum chemokine levels in Hodgkin lymphoma patients: highly increased levels of CCL17 and CCL22","volume":"140","author":"Niens","year":"2008","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2019.101931_b0330","doi-asserted-by":"crossref","first-page":"5716","DOI":"10.1158\/0008-5472.CAN-06-0261","article-title":"Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege","volume":"66","author":"Ishida","year":"2006","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101931_b0335","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1084\/jem.194.6.847","article-title":"Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells","volume":"194","author":"Iellem","year":"2001","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0340","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1158\/2326-6066.CIR-17-0325","article-title":"Complex immune evasion strategies in classical hodgkin lymphoma","volume":"5","author":"Wein","year":"2017","journal-title":"Cancer Immunol Res"},{"key":"10.1016\/j.ctrv.2019.101931_b0345","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20140559","article-title":"VEGF-A modulates expression of inhibitory checkpoints on CD8+ T cells in tumors","volume":"212","author":"Voron","year":"2015","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0350","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1158\/0008-5472.CAN-12-2325","article-title":"VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer","volume":"73","author":"Terme","year":"2013","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101931_b0355","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1007\/s00277-017-3115-6","article-title":"PD-L1 expression correlates with VEGF and microvessel density in patients with uniformly treated classical Hodgkin lymphoma","volume":"96","author":"Koh","year":"2017","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.ctrv.2019.101931_b0360","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1634\/theoncologist.2018-0058","article-title":"Comprehensive genomic profiling of hodgkin lymphoma reveals recurrently mutated genes and increased mutation burden","volume":"24","author":"Liang","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2019.101931_b0365","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1399-0039.2008.01005.x","article-title":"HLA-G protein expression as a potential immune escape mechanism in classical Hodgkin's lymphoma","volume":"71","author":"Diepstra","year":"2008","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.ctrv.2019.101931_b0370","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1038\/leu.2014.201","article-title":"The mutational landscape of Hodgkin lymphoma cell lines determined by whole-exome sequencing","volume":"28","author":"Liu","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ctrv.2019.101931_b0375","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1182\/blood-2014-11-610436","article-title":"Flow sorting and exome sequencing reveal the oncogenome of primary Hodgkin and Reed-Sternberg cells","volume":"125","author":"Reichel","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0380","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1200\/JCO.2006.10.0917","article-title":"HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma","volume":"25","author":"Diepstra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.101931_b0385","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nature09754","article-title":"MHC class II transactivator CIITA is a recurrent gene fusion partner in lymphoid cancers","volume":"471","author":"Steidl","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2019.101931_b0390","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1084\/jem.20100637","article-title":"Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients","volume":"207","author":"Fourcade","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0395","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1084\/jem.20100643","article-title":"Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity","volume":"207","author":"Sakuishi","year":"2010","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0400","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1182\/bloodadvances.2017007260","article-title":"Th17 immune microenvironment in Epstein-Barr virus-negative Hodgkin lymphoma: implications for immunotherapy","volume":"1","author":"Duffield","year":"2017","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2019.101931_b0405","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1182\/blood-2006-04-015164","article-title":"Expression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patients","volume":"108","author":"Gandhi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0410","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.3324\/haematol.2018.196279","article-title":"Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment","volume":"104","author":"Sasse","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.ctrv.2019.101931_b0415","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0204870","article-title":"Expression of PD-1 and PD-L1 increase in consecutive biopsies in patients with classical Hodgkin lymphoma","volume":"13","author":"Hollander","year":"2018","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.101931_b0420","doi-asserted-by":"crossref","first-page":"200ra116","DOI":"10.1126\/scitranslmed.3006504","article-title":"Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells","volume":"5","author":"Spranger","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0425","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.pharmthera.2018.12.004","article-title":"Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence","volume":"196","author":"Ricciuti","year":"2019","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.ctrv.2019.101931_b0430","doi-asserted-by":"crossref","first-page":"405","DOI":"10.3109\/10428194.2013.804917","article-title":"Up-regulated expression of indoleamine 2,3-dioxygenase 1 in non-Hodgkin lymphoma correlates with increased regulatory T-cell infiltration","volume":"55","author":"Liu","year":"2014","journal-title":"Leuk Lymphoma"},{"issue":"335","key":"10.1016\/j.ctrv.2019.101931_b0435","article-title":"Indoleamine 2,3-dioxygenase (IDO) is frequently expressed in stromal cells of Hodgkin lymphoma and is associated with adverse clinical features: a retrospective cohort study","volume":"14","author":"Choe","year":"2014","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2019.101931_b0440","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/cas.13432","article-title":"Clinical significance of tryptophan catabolism in Hodgkin lymphoma","volume":"109","author":"Masaki","year":"2018","journal-title":"Cancer Sci"},{"key":"10.1016\/j.ctrv.2019.101931_b0445","doi-asserted-by":"crossref","first-page":"E3837","DOI":"10.3390\/ijms19123837","article-title":"Targeting adenosine receptor signaling in cancer immunotherapy","volume":"19","author":"Sek","year":"2018","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2019.101931_b0450","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1158\/0008-5472.CAN-17-2826","article-title":"A2AR adenosine signaling suppresses natural killer cell maturation in the tumor microenvironment","volume":"78","author":"Young","year":"2018","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101931_b0455","doi-asserted-by":"crossref","first-page":"304","DOI":"10.3389\/fimmu.2014.00304","article-title":"Extracellular adenosine-mediated modulation of regulatory T cells","volume":"5","author":"Ohta","year":"2014","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2019.101931_b0460","doi-asserted-by":"crossref","DOI":"10.4161\/onci.26246","article-title":"A CD38\/CD203a\/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes","volume":"2","author":"Horenstein","year":"2013","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2019.101931_b0465","first-page":"172","article-title":"Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model","volume":"4","author":"Iannone","year":"2014","journal-title":"Am J Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2019.101931_b0470","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1007\/s00262-018-2186-0","article-title":"Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models","volume":"67","author":"Leone","year":"2018","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2019.101931_b0475","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1182\/blood-2012-05-428896","article-title":"Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma","volume":"120","author":"Tiacci","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2019.101931_b0480","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1001\/jamaoncol.2017.1617","article-title":"Use of PD-1 targeting, macrophage infiltration, and IDO pathway activation in sarcomas: A phase 2 clinical trial","volume":"4","author":"Toulmonde","year":"2018","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.ctrv.2019.101931_b0485","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1158\/1078-0432.CCR-18-3041","article-title":"A variant of a killer cell immunoglobulin-like receptor is associated with resistance to PD-1 blockade in lung cancer","volume":"25","author":"Trefny","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2019.101931_b0490","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cellimm.2014.02.005","article-title":"The role of indoleamine 2,3-dioxygenase (IDO) in immune tolerance: focus on macrophage polarization of THP-1 cells","volume":"289","author":"Wang","year":"2014","journal-title":"Cell Immunol"},{"key":"10.1016\/j.ctrv.2019.101931_b0495","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1084\/jem.171.5.1393","article-title":"LAG-3, a novel lymphocyte activation gene closely related to CD4","volume":"171","author":"Triebel","year":"1990","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2019.101931_b0500","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.immuni.2016.05.001","article-title":"Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation","volume":"44","author":"Anderson","year":"2016","journal-title":"Immunity"},{"key":"10.1016\/j.ctrv.2019.101931_b0505","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1182\/blood-2006-03-006700","article-title":"The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function","volume":"108","author":"Della Chiesa","year":"2006","journal-title":"Blood"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219301525?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219301525?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:21:09Z","timestamp":1759656069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737219301525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":101,"alternative-id":["S0305737219301525"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.101931","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.101931","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101931"}}